Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…Abstract Number: 1485 • 2013 ACR/ARHP Annual Meeting
RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept
Background/Purpose: Biologics, including abatacept (CTLA4Ig), improve outcomes for many RA patients. However, approximately 40-50% of RA patients fail to respond to abatacept, and there are…Abstract Number: 1486 • 2013 ACR/ARHP Annual Meeting
High Resolution HLA Analysis In Primary and Secondary Sjögren’s Syndrome
Background/Purpose: The Class II HLA-DR and HLA-DQ alleles have been associated with primary Sjögren’s Syndrome (SS) susceptibility. The aim of this study was to explore…Abstract Number: 1488 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren’s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren’s Syndrome (ASSESS) Cohort
Background/Purpose: In primary Sjögren’s syndrome (pSS), the pathogenesis of systemic complications remains unclear. Only few gene expression studies were performed and concerned a limited number…Abstract Number: 1489 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…Abstract Number: 1490 • 2013 ACR/ARHP Annual Meeting
Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjögren’s Syndrome Patients Versus Healthy Controls Based On RNA-Seq
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disease characterized by a progressive hypofunction of the salivary and lachrymal glands. In order to better…Abstract Number: 1491 • 2013 ACR/ARHP Annual Meeting
Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren’s Syndrome Patients
Background/Purpose: Sjögren's syndrome is a complex autoimmune disease of the salivary gland with an unknown etiology, so a thorough characterization of the transcriptome would facilitate…Abstract Number: 1494 • 2013 ACR/ARHP Annual Meeting
Increased Expression Of Interleukin 33 In Sera and Salivary Gland From Patients With Sjögren Syndrome
Background/Purpose: Interleukin 33 (IL-33), a member of IL-1 superfamily, exerts pro-inflammatory effect by binding with ST2 expressed on many cell types. Recently, the association of…Abstract Number: 1495 • 2013 ACR/ARHP Annual Meeting
Lesional Intereukin-21 Expression Correlates With Functional Germinal Center Formation and T Follicular Helper Cell Infiltration In The Salivary Glands Of Sjogren’s Syndrome
Background/Purpose: IL-21 is a pro-inflammatory cytokine that plays a key role in the activation and differentiation of B cells. B cells infiltrate the salivary glands…Abstract Number: 1496 • 2013 ACR/ARHP Annual Meeting
DNA Methylation In Six Cell and Tissue Types In Sjögren’s Syndrome Reveals Distinct Patterns Across Samples and Clustering Based On Disease Status
Background/Purpose: Sjögren’s Syndrome (SS) is a chronic, multisystem autoimmune disease characterized by progressive destruction of the exocrine glands, with subsequent mucosal and conjunctival dryness. Increasing…Abstract Number: 1497 • 2013 ACR/ARHP Annual Meeting
Endosomal TLR Triggering Of B Cells In Sjögren’s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production
Background/Purpose: Patients with primary Sjögren’s syndrome have B cell disturbances resulting in hypergammaglobulinemia and autoantibody production. Most patients are not treated by immunomodulatory drugs, enabling…Abstract Number: 1498 • 2013 ACR/ARHP Annual Meeting
Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren’s Patients
Background/Purpose: Neurotransmitter stimulation of fluid secretion in salivary glands is regulated by increases in intracellular calcium concentration. The increase in cytosolic calcium triggers ion channel…Abstract Number: 1499 • 2013 ACR/ARHP Annual Meeting
Detection Of CD4+CD25lowGITR+ T Lymphocytes In Sjogren’s Syndrome-Interstitial Lung Disease
Background/Purpose: CD4+CD25lowGITR+ T lymphocytes expressing FoxP3 and showing regulatory function have been recently described in healthy donors (HD). The objective of this study was to…Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…